Stockholders Equity (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 02, 2020
$ / shares
|
May 05, 2020
$ / shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Oct. 31, 2021
USD ($)
$ / shares
shares
|
Jul. 26, 2021
USD ($)
$ / shares
shares
|
Mar. 30, 2021
$ / shares
|
Dec. 31, 2020
$ / shares
shares
|
Mar. 25, 2020
$ / shares
shares
|
Oct. 28, 2019
shares
|
Dec. 18, 2018
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2019
$ / shares
|
Jul. 28, 2021
shares
|
Mar. 10, 2021
shares
|
Nov. 30, 2017
shares
|
May 31, 2017
$ / shares
shares
|
|
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Common stock, authorized | 60,000,000 | 60,000,000 | 60,000,000 | 60,000,000 | |||||||||||||
| Market sales agreement, description | pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Issuance Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock having an aggregate offering price of up to $50,000 through Jefferies acting as sales agent. During the year ended December 31, 2021, the Company sold 743,964 shares of Common Stock under the ATM Agreement, at an average price of $7.19 per share, raising aggregate net proceeds of approximately $5,188, after deducting an aggregate commission of 3%. During the year ended December 31, 2020, the Company sold 10,176 shares of Common Stock under the ATM Agreement, at an average price of $6.07 per share, raising aggregate net proceeds of approximately $60, after deducting an aggregate commission of 3%. | ||||||||||||||||
| Issuance expenses from additional paid in capital (in Dollars) | $ | $ 2 | $ 158 | |||||||||||||||
| Preferred stock, shares authorized | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||
| Preferred stock, par value (in Dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||
| Warrant expire date | 5 years | ||||||||||||||||
| Public warrants, description | ●in whole and not in part; ●at a price of $0.01 per warrant; ●at any time during the exercise period; ●upon a minimum of 30 days prior written notice of redemption; ●if, and only if, the last sale price of the Company’s Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ●if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. | ||||||||||||||||
| Shares issued | 362,383 | ||||||||||||||||
| Fair value at the grant date (in Dollars) | $ | $ 5,138 | $ 3,752 | |||||||||||||||
| Warrants to purchase common stock | 236,552 | 236,552 | |||||||||||||||
| Shares of issued warrants | 362,444 | ||||||||||||||||
| Recognized expense income (in Dollars) | $ | $ 233 | ||||||||||||||||
| Warrants, description | a.177,414 upon the filing of a patent application covering any Discovered Target or a Product (both as defined in the 2017 License Agreement). In 2020 the warrants were forfeited following termination of the 2017 License Agreement, b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company’s licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. In the case of termination of the 2017 License Agreement after the second anniversary thereof, and provided that none of the aforementioned milestones has been attained prior to such termination, the warrants will vest upon such termination. As of December 31, 2020, 118,277 warrants were vested as the 2017 License Agreement was terminated after the second anniversary with no milestone have been attained. c.59,139 upon completion of a Phase 1 clinical trial in respect of a Product (as defined in the 2017 License Agreement). In 2020 the warrants were forfeited following the termination of the 2017 License Agreement. | ||||||||||||||||
| Share based compensation expenses (in Dollars) | $ | $ 1,102 | $ 1,384 | |||||||||||||||
| Stock Options [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Grant options (in Dollars per share) | $ / shares | $ 32,000 | $ 79,000 | $ 985,530 | ||||||||||||||
| Employees consideration, description | On March 30, 2021, the Board approved the grant of 985,530 options to 94 employees, including five senior officers, one consultant, and six directors under the 2019 Plan, without consideration. | On March 25, 2020, the Board approved the grant of 814,700 options without consideration to 65 employees, one consultant, four senior officers (one of whom is also a consultant), and six directors under the 2019 Plan. | |||||||||||||||
| Grant approved | 814,700 | ||||||||||||||||
| Employees consideration | 4 | 65 | |||||||||||||||
| Exercise price (in Dollars per share) | $ / shares | $ 6.44 | $ 5.59 | $ 7.02 | $ 6.21 | |||||||||||||
| Vesting period | 4 years | 4 years | 4 years | ||||||||||||||
| Number of directors | 2 | ||||||||||||||||
| Stock option (in Dollars) | $ | $ 3,395 | $ 3,395 | |||||||||||||||
| Stock option weighted-average period | 1 year 5 months 4 days | ||||||||||||||||
| Securities Purchase Agreement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Aggregate shares | 3,750,000 | ||||||||||||||||
| Gross proceeds (in Dollars) | $ | $ 15,000 | ||||||||||||||||
| Sold price, per share (in Dollars per share) | $ / shares | $ 4 | ||||||||||||||||
| Accompanying warrant to purchase share | 0.75 | ||||||||||||||||
| Exercise price (in Dollars per share) | $ / shares | $ 5 | ||||||||||||||||
| Warrants exercisable description | The warrants will be exercisable six months after the date of issuance and will expire five years from the date such warrant first becomes exercisable. | ||||||||||||||||
| Shares sold to related parties | 125,000 | ||||||||||||||||
| Warrants sold to related parties | 93,750 | ||||||||||||||||
| Maruho Agreement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Total gross proceed (in Dollars) | $ | $ 3,000 | ||||||||||||||||
| Common stock per share (in Dollars per share) | $ / shares | $ 8 | ||||||||||||||||
| Common stock shares issued | 375,000 | ||||||||||||||||
| Grant date fair value (in Dollars) | $ | $ 1,024 | ||||||||||||||||
| Contract liability (in Dollars) | $ | $ 1,976 | ||||||||||||||||
| CFF Agreement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Agreement type, description | the Company entered into a Securities Purchase Agreement with the Cystic Fibrosis Foundation ("CF Foundation"), an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company would have the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion is less than $2.57, the Company shall have the right in its sole discretion to waive the second tranche payment and in such event the CF Foundation shall not have any right to receive additional shares. However, the CF foundation may waive the Milestone in its discretion and make the Milestone Payment nonetheless. The Company concluded that the second tranche is a freestanding financial instrument. | ||||||||||||||||
| License Agreement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Common stock per share (in Dollars per share) | $ / shares | $ 0.0001 | ||||||||||||||||
| Warrants to purchase common stock | 591,382 | ||||||||||||||||
| BiomX Israel [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Exchange for common shares | 15,069,058 | ||||||||||||||||
| Shares outstanding, percentage | 65.00% | ||||||||||||||||
| Earnout shares, description | A.2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. As of December 31, 2021, the condition was not achieved and the Company’s conditional undertaking to issue additional shares expired. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C.2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. | ||||||||||||||||
| IPO [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Consummated initial public offering | 7,000,000 | ||||||||||||||||
| Offering price (in Dollars per share) | $ / shares | $ 10 | ||||||||||||||||
| Total gross proceed (in Dollars) | $ | $ 70,000 | ||||||||||||||||
| Common stock per share (in Dollars per share) | $ / shares | $ 11.5 | ||||||||||||||||
| Retained transaction (in Dollars) | $ | $ 60,100 | ||||||||||||||||
| Private Placement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Aggregate warrants shares | 2,900,000 | ||||||||||||||||
| Yeda [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Shares of issued warrants | 7,615 | ||||||||||||||||
| Founder [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Shares of issued warrants | 2,974 | ||||||||||||||||
| Minimum [Member] | Stock Options [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Vesting period | 3 years | ||||||||||||||||
| Maximum [Member] | Stock Options [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Vesting period | 4 years | ||||||||||||||||
| 2019 Plan [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Grant options (in Dollars per share) | $ / shares | $ 1,000 | ||||||||||||||||
| Equity incentive plan, description | The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. | ||||||||||||||||
| Shares issued | 216,036 | 216,036 | |||||||||||||||
| Shares increased | 1,190,129 | 1,190,129 | |||||||||||||||
| Common Stock [Member] | Securities Purchase Agreement [Member] | |||||||||||||||||
| Stockholders Equity (Details) [Line Items] | |||||||||||||||||
| Aggregate shares | 2,812,501 | ||||||||||||||||